S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The single greatest medical breakthrough of all time? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NASDAQ:ANEB

Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price & News

$3.06
+0.03 (+0.99%)
(As of 09/29/2023 ET)
Compare
Today's Range
$3.05
$3.19
50-Day Range
$2.16
$3.48
52-Week Range
$1.77
$4.05
Volume
1,663 shs
Average Volume
6,677 shs
Market Capitalization
$78.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Anebulo Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
118.2% Upside
$6.67 Price Target
Short Interest
Healthy
0.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Anebulo Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

601st out of 970 stocks

Pharmaceutical Preparations Industry

286th out of 449 stocks


ANEB stock logo

About Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

ANEB Price History

ANEB Stock News Headlines

Overlooked AI Stock Gets Urgent "Buy"
We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.
H.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Anebulo Pharmaceuticals (ANEB) Has a New Rating from H.C. Wainwright
See More Headlines
Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANEB Company Calendar

Last Earnings
11/12/2021
Today
9/30/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANEB
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+118.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-11,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.65 per share

Miscellaneous

Free Float
3,666,000
Market Cap
$78.30 million
Optionable
Not Optionable
Beta
-1.39
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Joseph F. Lawler M.D. (Age 51)
    Ph.D., Founder & Chairman
    Comp: $11k
  • Mr. Simon J. Allen B.Sc. (Age 55)
    M.B.A., MBA, CEO & Director
    Comp: $450k
  • Dr. Kenneth C. Cundy Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $345.53k
  • Ms. Sandra A. Gardiner (Age 57)
    Acting Chief Financial Officer
  • Mr. Scott L. Anderson
    Head of Investor Relations & Public Affairs













ANEB Stock - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings
or view top-rated stocks.

What is Anebulo Pharmaceuticals' stock price forecast for 2023?

3 Wall Street research analysts have issued twelve-month price targets for Anebulo Pharmaceuticals' stock. Their ANEB share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 118.2% from the stock's current price.
View analysts price targets for ANEB
or view top-rated stocks among Wall Street analysts.

How have ANEB shares performed in 2023?

Anebulo Pharmaceuticals' stock was trading at $2.4237 at the start of the year. Since then, ANEB shares have increased by 26.0% and is now trading at $3.0550.
View the best growth stocks for 2023 here
.

Are investors shorting Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 13,900 shares, an increase of 1,444.4% from the August 31st total of 900 shares. Based on an average trading volume of 6,300 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.5% of the company's stock are sold short.
View Anebulo Pharmaceuticals' Short Interest
.

When is Anebulo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ANEB earnings forecast
.

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04.

When did Anebulo Pharmaceuticals IPO?

(ANEB) raised $21 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.

What is Anebulo Pharmaceuticals' stock symbol?

Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB."

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anebulo Pharmaceuticals' stock price today?

One share of ANEB stock can currently be purchased for approximately $3.06.

How much money does Anebulo Pharmaceuticals make?

Anebulo Pharmaceuticals (NASDAQ:ANEB) has a market capitalization of $78.30 million. The company earns $-11,730,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How can I contact Anebulo Pharmaceuticals?

The official website for the company is www.anebulo.com. The company can be reached via phone at 512-598-0931 or via email at ybriggs@lhai.com.

This page (NASDAQ:ANEB) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -